{"id":"somatropin-rdna-origin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Somatropin mimics endogenous human growth hormone by activating growth hormone receptors on target tissues, promoting linear growth in children, increasing lean body mass, decreasing fat mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of the anabolic and growth-promoting effects of growth hormone.","oneSentence":"Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:30.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children"},{"name":"Growth hormone deficiency in adults"},{"name":"Short stature associated with Turner syndrome"},{"name":"Chronic kidney disease-related growth failure"}]},"trialDetails":[{"nctId":"NCT00663611","phase":"PHASE1","title":"Growth Hormone Administration and the Human Immune System","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2006-10-19","conditions":"Healthy Volunteers","enrollment":66},{"nctId":"NCT06448195","phase":"PHASE4","title":"Effects of Growth Hormone Therapy on Metabolic Function in Fatty Liver Post-Pituitary Adenoma Surgery","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-01-01","conditions":"Growth Hormone Treatment","enrollment":40},{"nctId":"NCT00742157","phase":"PHASE4","title":"Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2003-09-01","conditions":"Short Bowel Syndrome","enrollment":5},{"nctId":"NCT00572156","phase":"PHASE2","title":"rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency","status":"TERMINATED","sponsor":"Ipsen","startDate":"2007-12","conditions":"Insulin-like Growth Factor-1 Deficiency","enrollment":106},{"nctId":"NCT04121780","phase":"PHASE2","title":"Growth Hormone Replacement Therapy for Retried Professional Football Players","status":"RECRUITING","sponsor":"Center for Neurological Studies","startDate":"2019-10-08","conditions":"TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury","enrollment":42},{"nctId":"NCT00747604","phase":"","title":"IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex","status":"TERMINATED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Primary Insulin-like Growth Factor-1 Deficiency","enrollment":1378},{"nctId":"NCT02420353","phase":"PHASE2","title":"Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-05","conditions":"Rupture of Anterior Cruciate Ligament","enrollment":20},{"nctId":"NCT00234533","phase":"PHASE3","title":"Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq","status":"COMPLETED","sponsor":"Ipsen","startDate":"2004-06","conditions":"Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases","enrollment":251},{"nctId":"NCT01438801","phase":"PHASE4","title":"Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)","status":"WITHDRAWN","sponsor":"Ipsen","startDate":"2013-05","conditions":"Idiopathic Short Stature","enrollment":""},{"nctId":"NCT01088412","phase":"","title":"Observational Study of Somatropin Treatment in Children","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"1999-04","conditions":"Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency, SHOX Deficiency-related Disorder","enrollment":22845},{"nctId":"NCT00455884","phase":"","title":"A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Growth Hormone Disorders","enrollment":546},{"nctId":"NCT02311894","phase":"PHASE4","title":"A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-03-31","conditions":"Growth Hormone Deficiency","enrollment":82},{"nctId":"NCT00455728","phase":"","title":"A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Growth Hormone Disorders","enrollment":3690},{"nctId":"NCT00511329","phase":"PHASE2, PHASE3","title":"Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","startDate":"2007-08","conditions":"Arthritis, Juvenile Rheumatoid, Crohn Disease","enrollment":10},{"nctId":"NCT00249821","phase":"PHASE3","title":"Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-02-28","conditions":"Small Gestational Age (SGA)","enrollment":22},{"nctId":"NCT00097539","phase":"","title":"National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"1985-10","conditions":"Growth Disorders","enrollment":65205},{"nctId":"NCT01088399","phase":"","title":"A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-09","conditions":"Hypopituitarism, Pituitary Insufficiency, Growth Hormone Deficiency, Adult","enrollment":10673},{"nctId":"NCT00455260","phase":"PHASE1","title":"A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2007-04","conditions":"Growth Hormone Deficiency","enrollment":60},{"nctId":"NCT00190658","phase":"PHASE3","title":"Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2000-02","conditions":"Failure to Thrive","enrollment":75},{"nctId":"NCT00600808","phase":"PHASE2, PHASE3","title":"Sustained Release Formulation of Somatropin (rDNA Origin)for Injection","status":"COMPLETED","sponsor":"BioPartners GmbH","startDate":"2003-06","conditions":"Growth Hormone Deficiency","enrollment":51},{"nctId":"NCT00191360","phase":"PHASE3","title":"Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-01","conditions":"Adult Growth Hormone Deficiency","enrollment":68},{"nctId":"NCT00191074","phase":"PHASE3","title":"Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-02","conditions":"Growth Disorder","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humatrope","LY137998"],"phase":"phase_3","status":"active","brandName":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatropin (rDNA origin) is a protein-based growth hormone receptor agonist used to treat conditions such as growth hormone disorders, growth hormone deficiency, and growth disorder. It is administered via injection and has been studied in clinical trials for various indications, including arthritis, juvenile rheumatoid arthritis, and Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}